title: Granulomatous disease in a child treated with etanercept.
authors.forename: Mariym
authors.initials: M
authors.lastname: Alhajri
authors.forename: Suliman
authors.initials: S
authors.lastname: Aljumaah
authors.forename: Yousef
authors.initials: Y
authors.lastname: Aleyouni
authors.forename: Faisal
authors.initials: F
authors.lastname: Al-Qahtani
authors.forename: Selwa
authors.initials: S
authors.lastname: Alhazzaa
authors.forename: Sulaiman M
authors.initials: SM
authors.lastname: Al-Mayouf
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D008727:Methotrexate